Company
Opthea Ltd
ASX:OPT
Opthea Ltd (ASX:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases.
11 stories
Investments and investor services
Small and mid-cap companies will be showcased during inaugural ASX conference
The inaugural ASX Small and Mid-Cap Conference will be held in Sydney on Thursday, September 6.
Opthea doses first patients in Europe and Israel in trial of macular degeneration treatment
The latest Phase 2b trial activations follow the first dosings at US clinical sites in December 2017.
Opthea starts clinical trial for diabetic blindness treatment
OPT-302 targets the leading cause of blindness in diabetics.
Opthea secures U.S. patent for its molecule to treat eye diseases
Age-related macular degeneration is the leading cause of blindness in the developed world.
Opthea Ltd secures notice of allowance for key U.S. patent
U.S. patent expected to be granted in the second half of 2017.
Opthea raises $45M to advance novel therapy for eye diseases
The new funds will accelerate Opthea’s clinical development strategy.
Opthea reveals positive trial results; launches $45M equity raising
The primary safety endpoint of the clinical trial has been met.
Opthea receives positive feedback for macular degeneration therapy
Opthea has concluded scientific advice meetings in the UK and Sweden.